Type Aktiengesellschaft Headquarters Germany Number of employees 55 (2014) | Website www.noxxon.com Founded 1997 | |
 | ||
Key people Aram Mangasarian, CEO
Hubert Birner, Chairman of the supervisory board
Jens P. Furste, Founder Stock price ALNOX (EPA) € 21.90 0.00 (0.00%)20 Mar, 3:30 PM GMT+1 - Disclaimer | ||
Noxxon Pharma AG is a small-to-medium-sized company founded in year 1997 in Berlin, Germany and since then is headquartered there. The stocks of the company are not publicly traded. Noxxon is a registered trademark and represents a palindrome.
Noxxon Pharma develops drugs under a patented technology yielding L-RNA molecules, which are of mirror-image configuration compared to natural occurring D-RNA molecules. This class of agents is termed Spiegelmer, which is a registered trademark of Noxxon Pharma AG., from Spiegel, the German word for "mirror." The company is member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa).
Products
While no Spiegelmer is on the market yet, some candidates are in clinical trials. Drug candidates for different diseases (indications) are evaluated:
In the area of oncology a Spiegelmer is under development for treatment of Multiple myeloma (MM) and Chronic lymphocytic leukemia (CLL).
A different Spiegelmer is currently being tested for the treatment of a progressive kidney disease in diabetics, Diabetic nephropathy. Favorable results were reported in June, 2014 in a company press release.
A third Spiegelmer is currently in a clinical trial for the treatment of Anemia of chronic disease.